Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8REX

CryoEM structure of mouse GARP-lTGFbeta1 in complex with a Fab fragment derived from an activating antibody.

8REX の概要
エントリーDOI10.2210/pdb8rex/pdb
EMDBエントリー19111
分子名称Transforming growth factor beta-1 proprotein, Transforming growth factor beta activator LRRC32, mFab LMT-12, Light Chain, ... (6 entities in total)
機能のキーワードgarp, tgf-b1, activation, treg, immune system, antibody
由来する生物種Mus musculus (house mouse)
詳細
タンパク質・核酸の鎖数9
化学式量合計354609.07
構造登録者
Felix, J.,Lambert, F.,Marien, L.,van der Woning, B.,Savvides, S.N.,Lucas, S. (登録日: 2023-12-12, 公開日: 2025-06-25, 最終更新日: 2025-10-08)
主引用文献Lambert, F.,Felix, J.,Wautier, S.,Dupre, E.,Jamez, M.,Michiels, C.,Gaignage, M.,Marien, L.,Lesage, M.,van der Woning, B.,Savvides, S.N.,Lucas, S.
Antibody-mediated TGF-beta 1 activation for the treatment of diseases caused by deleterious T cell activity.
Cell Rep, 44:116061-116061, 2025
Cited by
PubMed Abstract: Transforming growth factor β1 (TGF-β1) is an immunosuppressive cytokine produced as a latent homodimer, in which mature TGF-β1 is encapsulated and kept inactive by the latency-associated peptide (LAP). The transmembrane protein GARP presents latent TGF-β1 on the surface of regulatory T cells (Tregs) to enable activation and release of mature TGF-β1 by integrins. Here, we derived monoclonal antibodies (mAbs) that activate latent TGF-β1 anchored on cells by a transmembrane protein. Biochemical and structural studies by electron cryo-microscopy (cryo-EM) reveal that such mAb-mediated activation requires bivalent binding close to the LAP dimerization interface and crosslinking of two membrane-bound GARP:TGF-β1 complexes on the same cell or across different cells. Administration of mAbs to mice with graft versus host disease reduced disease severity and increased survival. The therapeutic effect required Tregs. Collectively, our findings demonstrate that activation of membrane-bound TGF-β1 in vivo is achievable with mAbs, introducing new immunotherapeutic options for allo- or autoimmune diseases characterized by deleterious T cell activity insufficiently controlled by Tregs.
PubMed: 40742810
DOI: 10.1016/j.celrep.2025.116061
主引用文献が同じPDBエントリー
実験手法
ELECTRON MICROSCOPY (3 Å)
構造検証レポート
Validation report summary of 8rex
検証レポート(詳細版)ダウンロードをダウンロード

249697

件を2026-02-25に公開中

PDB statisticsPDBj update infoContact PDBjnumon